Staffan has over 20 years of experience in the pharmaceutical industry. Besides his role as Head of Medical Devices at the Swedish Medical Products Agency, he has also been Vice President of Nicox France, and had management positions at AstraZeneca. Staffan has particularly experience in the development of orphan drugs as he was Head of R&D of Swedish Orphan.
Shareholding in the Company: 41,728 shares of series B and 70,000 warrants 2017/2022 and 50,000 warrants 2020/2024 and 45,864 shares of series B through the wholly-owned company Eteboxagu AB.
Chief Financial Officer since 2017. Born 1974.
Daniel has 20 years experience from diverse U.S. and international management positions in finance and accounting with Investors Bank & Trust Co., Nordea Investment Management AB and Nordea Bank AB.
Shareholding in the Company: 6,120 shares of series B and 50,000 warrants 2017/2022 and 40,000 warrants 2020/2024.
Anders Kronström, M.Sc., M.B.A.
Chief Operating Officer Since 2018. Born 1967.
Anders Kronström has over 20 years of experience working in the pharmaceutical industry. His experience spans across all stages of drug development in different disease segments. During his career at AstraZeneca he has had senior leadership positions within Project Management and Business Development. More recently, he was a CEO of Biosergen AS, a Norwegian biotechnology company.
Shareholding in the Company: 6 670 shares of series B and 50,000 warrants 2017/2022 and 40,000 warrants 2020/2024.
Professor Jonas Rastad, MD, Ph.D.
CHIEF MEDICAL OFFICER
Jonas has 20 years of experience in academic surgery and has published 250 papers in peer review journals. He has served in several managerial roles in AstraZeneca in Sweden, Japan, the UK and the US. He also has 13 years experience in senior public leadership roles including Head of County Hospital of Kalmar, Head of Västerbotten County Council and CEO of Region Skåne.
Holdings in Infant Bacterial Therapeutics AB as of March 29, 2021.